Heron Therapeutics (HRTX)
(Real Time Quote from BATS)
$1.72 USD
+0.03 (1.78%)
Updated Aug 4, 2025 10:26 AM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HRTX 1.72 +0.03(1.78%)
Will HRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRTX
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
HRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics
Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates
MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise
Other News for HRTX
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 | ...
Heron Therapeutics: Middling Performance From Approved Therapies With No Pipeline
JW Asset Management, LLC Adjusts Position in Establishment Labs Holdings Inc
Heron Therapeutics Holds Annual Stockholders Meeting
Edison, Apple, Oklo, Heron, Fifth Third: Trending by Analysts